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BACKGROUND AND PURPOSE 
Fibroblast growth factor 21 (FGF21) has emerged as a therapeutic strategy for treating type 2 
diabetes mellitus due to its antidiabetic effects, and this has led to the development of FGF21 
long-acting analogs. These compounds have some limitations, including requiring 
subcutaneous injection and their prolonged pharmacodynamic effect compared with native 
FGF21, which might be responsible for their reported side effects.  
EXPERIMENTAL APPROACH 
We have previously demonstrated that intraperitoneal administration of heme-regulated 
eukaryotic translation initiation factor 2α (eIF2α) kinase (HRI) activators increases hepatic 
and circulating levels of FGF21. In this study, we examined the effects of oral administration 
of a new HRI activator, EPB-53, on high-fat diet (HFD)-induced glucose intolerance, hepatic 
steatosis, and hypertriglyceridemia, compared with metformin. 
KEY RESULTS 
Administration of EPB-53 administration for the last two weeks, to mice fed a HFD for 10 
weeks, reduced body weight gain, improved glucose intolerance, and prevented hepatic 
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steatosis and hypertriglyceridemia; whereas metformin only ameliorated glucose intolerance. 
Moreover, EPB-53, similarly to the reported effects of FGF21, reduced lipogenesis in 
cultured human hepatocytes and in the liver of mice fed a HFD. Administration of EPB-53 to 
Fgf21-knockout mice had no effects, demonstrating that its efficacy is dependent on this 
hormone.  
CONCLUSIONS AND IMPLICATIONS 
Overall, the findings of this study demonstrate that oral administration of HRI activators is a 
promising strategy for the treatment of type 2 diabetes mellitus and non-alcoholic fatty liver 
disease by increasing FGF21. 
 
Abbreviations: Acox, acyl-CoA oxidase; AMPK, AMP-activated protein kinase; ATF4, 
activating transcription factor 4; BTCtFPU, 1-(benzo[d][1,2,3]thiadiazol-6-yl)-3-(4-chloro-3-
(trifluoromethyl)phenyl)urea; BTdCPU, 1-(benzo[d][1,2,3]thiadiazol-6-yl)-3-(3,4-
dichlorophenyl)urea; Chop, C/EBP homologous protein; Cpt-1α, carnitine palmitoyl-
transferase 1 α; eIF2eukaryotic translation initiation factor 2 FGF21, fibroblast growth 
factor 21; HFD, high-fat diet; Hmgcs2, 3-hydroxy-3-methylglutaryl-CoA synthase 2; HRI, 
heme-regulated eIF2kinase; Hsd3b5, 3--hydroxysteroid dehydrogenase type 5; Mcad, 
medium-chain acyl-CoA dehydrogenase; Mup1, major urinary protein 1; NAFLD, non-
alcoholic fatty liver disease; PGC-1PPAR co-activator 1 PPAR peroxisome 
proliferator-activated receptor.  
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Bullet point summary 
 
What is already known: Targeting FGF21 is an emerging therapeutic strategy for treating 
type 2 diabetes mellitus. 
What this study adds: Oral administration of HRI activators improved glucose intolerance 
and prevented hepatic steatosis by increasing FGF21. 
Clinical significance: The use of an oral drug to induce endogenous FGF21 levels might 
have advantages over FGF21 analogs 
 
Introduction 
Fibroblast growth factor 21 (FGF21) is a secreted protein belonging to the FGF19 subfamily 
(Goetz et al., 2007). It elicits actions through binding to a plasma membrane receptor 
complex consisting of the FGF receptor 1c isoform (FGFR1c) and β-klotho co-receptor 
(Goetz et al., 2007; Ogawa et al., 2007). Circulating FGF21 is liver-derived (Markan et al., 
2014), and serum FGF21 levels correlate with hepatic expression (Hale et al., 2012). FGF21 
was originally identified as a fasting-induced hormone that promotes increased glucose 
uptake in adipocytes (Kharitonenkov et al., 2005). Later studies demonstrated that 
pharmacological administration of FGF21 to animal models of obesity and/or diabetes 
improved glucose tolerance and insulin sensitivity, reduced hepatic and serum triglyceride 
levels, and caused weight loss (Kharitonenkov et al., 2005; Ding et al., 2012; Coskun et al., 
2008; Inagaki et al., 2007; Xu et al., 2009). Despite these pharmacological effects, serum 
FGF21 levels are paradoxically increased in obesity, both in rodents (Hale et al., 2012; Zhang 
et al., 2008; Muise et al., 2008; Fisher et al., 2010; Satapati et al., 2008) and humans (Chavez 
et al., 2009; Chen et al., 2008; Mraz et al., 2009), and especially in type 2 diabetes mellitus 
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(T2DM) (Badman et al., 2009; Zhang et al., 2008). The presence of high endogenous FGF21 
levels in obesity has led to this condition being considered as an FGF21-resistant state (Fisher 
et al., 2010). However, this assumption is controversial, since, as mentioned above, 
exogenous pharmacological administration of FGF21 is effective in genetic and diet-induced 
animal models of obesity (Hale et al., 2012). The increase in circulating FGF21 levels in 
obesity and other metabolic alterations probably reflects deposition of fat in liver (Hale et al., 
2012; Maratos-Flier, 2017) and, consistent with this, serum FGF21 levels correlate with non-
alcoholic fatty liver disease (NAFLD) in humans (Dushay et al., 2010; Yilmaz et al., 2010). 
This assumption is also supported by the fact that administration of exogenous FGF21 
reduces its expression in liver as plasma and hepatic triglyceride levels decrease, or as 
adiposity and insulin resistance improve in animal models of obesity and insulin resistance 
(Hale et al., 2012).  
 
The beneficial effects of pharmacological administration of FGF21 have led to the 
establishment of FGF21 as a therapeutic target for the treatment of metabolic diseases 
(Gimeno and Moller,  2014; Kharitonenkov and DiMarchi, 2015). This has encouraged the 
development of FGF21 analogs to treat human metabolic disorders such as obesity, 
dyslipidemia, and T2DM (Reitman, 2013; Talukdar et al., 2016; Kim et al., 2017). However, 
because of their peptidic origin, these analogs require parenteral administration and, therefore, 
there is a need for more convenient orally available drugs targeting FGF21 to treat metabolic 
disorders. In addition, native FGF21 has a short half-life and, to overcome this issue, long-
acting FGF21 analogs, with prolonged pharmacodynamics compared to native FGF21, have 
been designed (Huang et al., 2007, Weng et al., 2015). However, prolonged activation of the 
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FGF21 receptor by these long-acting FGF21 analogs might be responsible for their side 
effects, including bone loss (Talukdar et al., 2016), and increases in blood pressure and heart 
rate (Kim et al., 2017).  
 
Recently, we reported that intraperitoneal administration of a heme-regulated eukaryotic 
translation initiation factor 2α (eIF2α) kinase (HRI) activator increases hepatic Fgf21 
expression and reduces lipid-induced hepatic steatosis and glucose intolerance in mice fed a 
high-fat diet (HFD) (Zarei et al., 2016). Those effects were dependent on FGF21, since they 
were abolished in Fgf21-null mice (Zarei et al., 2016). The activation of HRI resulted in the 
phosphorylation of eIF2α and the subsequent increase in the activity of activating 
transcription factor (ATF) 4, which is essential for Fgf21-induced expression (De Sousa-
Coelho et al., 2012). This converts HRI activators, which are small molecules, into potential 
candidates for an orally administered treatment of T2DM. In this study, we compare the oral 
effects of a new HRI activator, EPB-53 (Figure 1A), and metformin, on glucose tolerance, 
hepatic steatosis, and hypertriglyceridemia in mice fed a HFD. Our findings show that EPB-
53 treatment reduces body weight gain, glucose intolerance, hepatic steatosis, and 




N,N’-diarylureas, 1-(benzo[d][1,2,3]thiadiazol-6-yl)-3-(3,4-dichlorophenyl)urea (BTdCPU) 
and 1-(benzo[d][1,2,3]thiadiazol-6-yl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea 
(BTCtFPU), were synthesized as previously described (Zarei et al., 2016). Synthesis of EPB-
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53 is included in Supplementary Materials and Methods. Triglyceride (Sigma-Aldrich, 
Madrid, Spain), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
(Spinreact, Girona, Spain) and FGF21 (Millipore, Bedford, MA) levels were measured using 
a commercial kit. 
 
Mice  
Male C57BL/6 mice (10-12 weeks old) (Harlan Ibérica S.A., Barcelona, Spain) were housed 
and maintained under a constant temperature (22 ± 2°C) and humidity (55%). The mice had 
free access to water and food and were subjected to 12 h light-dark cycles. After 1 week of 
acclimatization, mice were randomly distributed in two experimental groups (n=6 each) and 
either received one daily oral gavage of vehicle (2% w/v, (2-hydroxypropyl)-β-cyclodextrin) 
or one daily oral dose of 300 mg · kg-1 · day-1 of the HRI activator EPB-53 dissolved in the 
vehicle (volume administered 1 ml kg-1) for 4 days. This high dose was selected because of 
the presence of two parameters that may lower efficacy, the poor solubility of the compound 
(ClogP=5.5) and its high plasma protein binding (99.85%). In a second study, male C57BL/6 
mice (10-12 weeks old) were randomly distributed into four experimental groups (n=6 each) 
and fed either standard chow (one group) or HFD (45% fat mainly form hydrogenated 
coconut oil, Product D08061110, Research Diets Inc.) for ten weeks. Mice fed standard chow 
and one of the groups of mice fed the HFD received one daily oral gavage of vehicle (2% 
w/v, (2-hydroxypropyl)-β-cyclodextrin)), meanwhile the remaining two groups fed the HFD 
received one daily oral dose of either the HRI activator EPB-53 (300 mg · kg-1 · day-1) or 
metformin (150 mg · kg-1 · day-1) (YS Kim et al., 2017), for the last 2 weeks. In a third study, 
male Fgf21 knockout (Fgf21-/-) mice (8-10 weeks old) (B6N;129S5-Fgf21tm1Lex/Mmcd, 
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obtained from the Mutant Mouse Regional Resource Centre; MMRRC) and their wild-type 
littermates (Fgf21+/+) were randomly distributed into three experimental groups (standard 
chow, HFD, and HFD+EPB-53; n=5 each) and fed the different diets for three weeks. The 
standard chow and HFD groups received one daily oral gavage of vehicle (2% w/v, (2-
hydroxypropyl)-β-cyclodextrin)), whereas the HFD+EPB-53 group received one daily oral 
administration of the HRI activator EPB-53 (300 mg · kg-1 · day-1) for the last week. These 
last conditions were reproduced for the dose-response study, where male C57BL/6 mice (10-
12 weeks old) fed a HFD for three weeks were treated during the last week with EPB-53 
(100, 200 and 300 mg · kg-1 · day-1).  
For the glucose tolerance test (GTT), animals received 2 g · kg-1 body weight of glucose by 
intraperitoneal injection, and blood was collected from the tail vein after 0, 15, 30, 60 and 120 
min.  
The research complied with the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). All 
procedures were approved by the University of Barcelona Bioethics Committee, as stated in 
Law 5/21 July 1995 passed by the Generalitat de Catalunya. The animals were treated 
humanely, and all efforts were made to minimize the animals' suffering and the animal 
numbers. Animal studies are reported in compliance with the ARRIVE guidelines (McGrath 
and Lilley, 2015). 
 
Pharmacokinetics 
CD-1 male mice were treated with EPB-53 via the oral route at a single dose of 20 mg · kg-1. 
Plasma samples were obtained from cava vein at 0, 0.5, 1, 3, 5, and 24 hours post-
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administration (3 mice/point). Analytical measurements were performed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters were 
calculated by means of non-compartmental analysis, Phoenix 7.0 (WinNonlin 6.3). 
 
Cell culture 
Human Huh-7 cells [RRID:CVCL_0336] (a kindly gift from Dr Mayka Sánchez, of the Josep 
Carreras Leukaemia Research Institute) were cultured in DMEM supplemented with 10% 
serum, at 37°C/5% CO2. Hepatocytes were exposed to a concentration of 10 µM of each 
diarylurea, as previously reported (Chen et al., 2011). 
 
RNA preparation and quantitative RT-PCR 
The relative levels of specific mRNAs were assessed by real-time RT-PCR, as previously 
described (Zarei et al., 2016). The results for the expression of specific mRNAs were 
normalized to the expression of a control gene to avoid unwanted sources of variation. The 
primer sequences used are displayed in Supplementary Table 1.  
 
Immunoblotting 
Isolation of total protein extracts was performed as described elsewhere (M Zarei et al., 
2016). Proteins (30 g) were separated by SDS-PAGE on 10% acrylamide separation gels 
and transferred to Immobilon polyvinylidene difluoride membranes (Millipore). Western blot 
analysis was performed using antibodies against ATF4 (sc-390063), GAPDH (sc-32233), 
HRI (sc-365239) (RRID:AB_10843794), VLDLR (sc-18824) (Santa Cruz Inc., Heidelberg, 
Germany), VLDLR (AF2258) (R&D Systems, Minneapolis, MN), AMPK (2532), p-AMPK 
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Thr172 (2535), eIF2α (9722), phospho-eIF2α (Ser51) (9721) (Cell Signaling Technology Inc., 
Danvers, MA), β-actin (A5441), and tubulin (T9026) (Sigma-Aldrich). Detection was 
performed using the Western Lightning® Plus-ECL chemiluminescence kit (PerkinElmer, 
Waltham, MA). The equal loading of proteins was assessed by Ponceau S staining. The size 
of detected proteins was estimated using protein molecular mass standards (Bio-Rad, 
Barcelona, Spain). The results for protein quantification were normalized to the levels of a 
control protein to avoid unwanted sources of variation. 
 
Hematoxylin-eosin and Oil Red O staining 
We performed hematoxylin-eosin and Oil Red O (ORO) staining as previously reported 
(Zarei et al., 2016).  
 
Statistical Analysis 
The data and statistical analysis comply with the recommendations on experimental design 
and analysis in pharmacology (Curtis et al., 2015; Curtis et al., 2018). For in vivo 
experiments animals were randomly distributed between groups and experimenters blinded 
for liver analysis purposes. Results are expressed as means  S.D. Significant differences 
were established by ANOVA, using the GraphPad Prism program (V6.01) 
(RRID:SCR_002798) (GraphPad Software Inc., San Diego, CA). When significant variations 
were found by one-way ANOVA, the Tukey-Kramer multiple comparison post-test was 
performed only if F achieved P<0.05 and there was no significant variance inhomogeneity. 
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Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017). 
 
Results 
EPB-53 increases FGF21 expression in human Huh-7 hepatocytes, and in liver and serum of 
mice 
It has previously been reported that N,N’-diarylureas, including BTCtFPU and BTdCPU, are 
activators of HRI and induce eIF2α phosphorylation (Chen et al., 2013). We demonstrated 
that intraperitoneal administration of both BTCtFPU and BTdCPU increased mouse hepatic 
and serum FGF21 levels (Zarei et al., 2016). Then, we synthesized a series of compounds 
featuring a diarylurea scaffold and screened these new compounds for their capacity to 
increase FGF21 expression in human Huh-7 hepatocytes. Of all these new compounds, we 
selected EPB-53 as the best candidate for in vivo studies, since it showed a significant 
increase in FGF21 mRNA levels compared to the previous HRI activators BTCtFPU and 
BTdCPU (Figure 1B), and it displayed a good pharmacokinetic profile in mice 
(Supplementary Table 2). Notably, the half-life of the elimination phase of EPB-53 by oral 
administration was 5.4 h in mice, thus allowing for a substantial period of activity after 
administration.  
As a first step to check the effects of EPB-53 on mice, we examined whether acute oral 
administration of EPB-53 for 4 days activated the HRI-eIF2α-ATF4 pathway and increased 
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hepatic expression and serum levels of FGF21. HRI is activated by autophosphorylation (Lu 
et al., 2001) and EPB-53 increased hepatic phospho-levels of HRI, compared to those of mice 
treated with the vehicle alone (Figure 2A). Consistent with the eIF2α kinase role of HRI, 
EPB-53 significantly enhanced phospho-eIF2α and ATF4 levels in liver (Figure 2A). 
Likewise, EPB-53 increased the hepatic expression and serum levels of FGF21 (Figure 2B 
and C).  
Next, we analyzed the expression of two additional ATF4-target genes: very-low-density 
lipoprotein receptor (VLDLR) (Jo et al., 2013) and CCAAT/enhancer-binding protein 
homologous protein (CHOP). VLDLR binds apolipoprotein E (apoE) triglyceride-rich 
lipoproteins such as chylomicrons, VLDL, and intermediate-density lipoproteins, leading to 
lipid entry into the cell. Notably, hepatic VLDLR upregulation plays an essential role in the 
triglyceride-lowering effect of fenofibrate (Gao et al., 2014). Meanwhile CHOP induces cell 
cycle arrest and apoptosis (Zinszner et al., 1998). EPB-53 treatment significantly increased 
the expression of Vldlr, but it did not affect Chop mRNA levels (Figure 2D).  
It has been suggested that acute administration of FGF21 upregulates the expression of the 
transcriptional co-activator PGC-1α (Fisher et al., 2011), which in turn controls the activity of 
the master regulator of hepatic fatty acid oxidation, PPARα (Kersten and Stienstra, 2017). 
Consistent with the increase in FGF21 levels following EPB-53 treatment, Pgc-1α expression 
tended towards upregulation, but the differences did not reach statistical significance. 
Although expression of Pparα was not affected, the increase in the expression of its target 
genes, Cpt-1α and Mcad, suggested an increase in its activity (Figure 2E). Moreover, it has 
been reported that FGF21 controls hepatic triglyceride content in liver by reducing de novo 
lipogenesis (Xu et al., 2009; Zhang et al., 2011). Consistent with the increase in FGF21 
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levels, the expression of the lipogenic gene fatty acid synthase (Fas) was downregulated 
(Figure 2E).  
 
EPB-53 administration improves glucose intolerance, hepatic steatosis and 
hypertriglyceridemia in mice fed a HFD 
Next, we examined the effects of EPB-53 on mice fed a HFD, a model of diet-induced 
obesity and T2DM. First, mice were fed the HFD for 10 weeks and the last 2 weeks they were 
treated with either the vehicle alone, EPB-53 or metformin. Mice treated with EPB-53 did not 
show any sign of discomfort or toxicity. We compared the effects of EPB-53 with metformin, 
the first-line drug treatment for T2DM. Mice fed the HFD for 10 weeks showed an increase 
of 17.2±1.6 g in body weight, compared to the 7.6±0.8 g observed in mice fed the standard 
diet (Figure 3A). EPB-53 treatment significantly reduced body weight gain (10.9±1.3 g); 
whereas the reduction observed with metformin was of lower intensity (14.3±1.8 g) (Figure 
3A). Drug treatment did not affect food intake (Supplementary Figure 1A). HFD feeding also 
increased basal glucose levels and this was prevented by EPB-53 and metformin (Figure 3B). 
In addition, glucose intolerance caused by the HFD was prevented by EPB-53 and by 
metformin (Figure 3C).  
 
Interestingly, EPB-53 administration abolished the hepatic steatosis caused by HFD feeding, 
as demonstrated by ORO and hematoxylin-eosin staining, and quantification of hepatic 
triglyceride levels (Figures 4A and B). In contrast, the trend towards a reduction in the 
accumulation of hepatic triglycerides caused by metformin did not reach statistical 
significance. Likewise, the 106% increase in serum triglyceride levels caused by the HFD was 
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nearly completely abolished by treatment with EPB-53; whereas metformin merely tended 
towards a slight reduction which was not significant (p<0.05 vs. mice fed the standard diet). 
Consistent with the reduction in hepatic triglyceride levels caused by EPB-53, this compound 
also prevented the increase in serum ALT and AST caused by the HFD, whereas metformin 
only significantly reduced ALT (Figures 4D and E). 
 
When we examined the HRI-eIF2α pathway, we observed that EPB-53 increased the levels of 
phospho-HRI and phospho-eIF2α, indicating that this compound activated this pathway, 
whereas metformin did not (Figure 5A). As expected, feeding mice a HFD increased the 
expression and serum levels of FGF21, and this was exacerbated in mice fed the HFD and 
treated with metformin (Figures 5B and C), which is consistent with the reported effects of 
metformin on FGF21 in liver and plasma (Kim et al., 2013). Surprisingly, mice fed the HFD 
and treated with EPB-53 showed Fgf21 mRNA and serum levels similar to those present in 
the control group (Figures 5B and C). However, this is consistent with the lack of hepatic 
steatosis in both groups, since FGF21 levels reflect deposition of fat in liver (Hale et al., 
2012; Maratos-Flier, 2017). Moreover, when we assessed the expression of two FGF21 target 
genes negatively regulated by this hormone, 3-β-hydroxysteroid dehydrogenase type 5 
(Hsd3b5), and major urinary protein 1 (Mup1) (Inagaki et al., 2008), we observed that the 
expression of these genes was reduced in the liver of mice fed the HFD and treated with EPB-
53 (Figures 5D and E), suggesting a previous increase in the activity of FGF21. In contrast, 
the increase in FGF21 in mice fed the HFD or the higher increase in mice fed the HFD and 
treated with metformin did not reduce the expression of these genes, suggesting the presence 
of FGF21 resistance.  
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Metformin acts via AMP-activated protein kinase (AMPK)-dependent mechanisms, although 
additional mechanisms have been reported (Rena et al., 2017). Consistent with this, treatment 
with this drug increased hepatic phospho-AMPK levels (Figure 5F). EPB-53 did not 
significantly affect AMPK phosphorylation, but it increased the protein levels of the ATF4 
target gene VLDLR (Figure 5F). Neither HFD feeding nor drug treatment affected the 
expression of the ATF4 target genes Trb3 or β-klotho (Supplementary Figure 1B and C). In 
contrast, EBP-53 significantly reduced the mRNA levels of Chop and both the HFD and 
EPB-53 reduced the expression of Fgfr1c (Supplementary Figure 1D and E, respectively). 
When we examined the expression of genes involved in fatty acid oxidation, the mRNA 
levels of Pparα and Cpt-1α were upregulated by the HFD, whereas the expression of the latter 
gene was not further increased by either EPB-53 or metformin treatment (Figure 6A). These 
findings suggest that an increase in fatty acid oxidation is not involved in the effects of EPB-
53 in hepatic steatosis. When we examined the expression of lipogenic genes, we observed 
that mice fed the HFD and those fed the HFD and also treated with metformin showed an 
increase in the mRNA levels of the lipogenic transcription factor Srebp1c (Figure 6B); 
whereas this was not observed in mice treated with EPB-53. Interestingly, EPB-53 treatment 
reduced the expression of the lipogenic genes stearoyl-CoA desaturase 1 (Scd1), Fas and 
glycerol phosphate acyltransferase (Gpat) (Figure 6B). EPB-53 also reduced the expression of 
the transcription factor carbohydrate-responsive element-binding protein (ChREBP): a major 
mediator of glucose action on lipogenic gene expression and a key determinant of lipid 
synthesis in vivo (Postic et al., 2007). Consistent with the increase in hepatic triglycerides, 
levels of the protein FAS were increased in the liver of mice fed the HFD, but this increase 
was attenuated by EPB-53 (Figure 6C). Moreover, the protein levels of PPARγ and its target 
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gene CD36, both involved in lipid accumulation, were increased in the livers of mice fed the 
HFD, and this increase was prevented by EPB-53, but not by metformin. The effects of EPB-
53 seemed not to be mediated by the reduction in body weight, since when we treated 
cultured human Huh-7 hepatocytes with EPB-53, a strong reduction in FAS and CD36 
expression was observed (Figure 6D), which is consistent with the strong increase in FGF21 
observed in these cells following exposure to EPB-53 (Figure 1B). Exposing hepatocytes to 
EPB-53 also increased expression of VLDLR (Figure 6D). 
 
Effects of EPB-53 on glucose intolerance, hepatic steatosis and hypertriglyceridemia are 
dependent on FGF21. 
Next, to examine whether EPB-53 displayed dose-response behavior, we fed mice with a 
HFD for three weeks and the last week mice were treated with three different doses of EPB-
53 (100, 200 or 300 mg · kg-1 · day-1). EPB-53 showed a dose-response trend in the 
parameters assessed (glucose intolerance, liver triglyceride content, hepatic Fgf21 and Fas 
expression) (Figure 7A-D).  
Finally, we examined whether the effects of EPB-53 were dependent on FGF21 by taking 
advantage of the use of Fgf21-knockout mice. In this experiment both wild-type and Fgf21-
knockout mice were fed a HFD for 3 weeks, the last week of which they were treated with 
either the vehicle alone or EPB-53. This shorter period of treatment was selected to examine 
whether EPB-53 increased the expression and serum levels of FGF21 in mice fed a HFD. In 
fact, the HFD increased the mRNA levels of FGF21 in the liver of wild-type mice and also 
the serum levels of this hormone (Figure 8A), but these changes were even higher in mice fed 
the HFD and treated with EPB-53. When we examined glucose intolerance (Figure 8B) and 
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hepatic steatosis by quantification of hepatic triglyceride levels and ORO and hematoxylin-
eosin staining (Figures 8C and D), we observed that EPB-53 ameliorated these conditions in 
wild-type mice fed a HFD, but not in Fgf21-knockout mice. Similarly, the reduction observed 
in serum triglycerides in wild-type mice fed the HFD and treated with EPB-53 compared with 
mice fed the HFD and treated with the vehicle alone, disappeared in Fgf21-knockout mice 
(Figure 8E). Finally, EPB-53 attenuated the increase in serum levels of ALT and AST (Figure 




FGF21 is a potential new target for obesity, T2DM and associated co-morbidities (Gimeno 
and Moller, 2014). This has raised interest in the potential of FGF21 to treat metabolic 
diseases. However, the use of wild-type native FGF21 is challenging as it has several 
limitations. One of these limitations is its short half-life ( Kharitonenkov et al., 2007), which 
has led to the development of long-acting FGF21 analogs with prolonged pharmacodynamic 
effects compared to native FGF21 (Huang et al., 2013; Hecht et al., 2013). However, this 
increase in the potency of long-acting FGF21 analogs may exacerbate some of the unwanted 
effects of FGF21, such as the reported increase in bone loss caused by this hormone (Wei et 
al., 2012). In fact, concerns raised following treatment with potent long-acting FGF21 
analogs in humans include changes in multiple markers of bone turnover (Talukdar et al., 
2016) and an increase in both blood pressure and heart rate (Kim et al., 2017). Another 
limitation to the use of FGF21 in humans is the need for subcutaneous administration, 
because, due to its simplicity and convenience, oral administration improves patient 
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compliance. Orally bioavailable drugs that increase the levels of native FGF21 might 
overcome all these limitations. We have previously reported that intraperitoneal 
administration of HRI activators increases hepatic and plasma levels of FGF21 through 
activation of the eIF2α-ATF4 pathway (Zarei et al., 2016). Based on those findings, we have 
developed new orally bioavailable HRI activators with enhanced potency, to increase FGF21 
expression in human hepatocytes; and we selected EPB-53 for an in vivo proof of concept. 
Administration of EPB-53 for 4 days to normal mice increased the hepatic expression and 
circulating levels of FGF21, and slightly upregulated the expression of genes involved in fatty 
acid oxidation; whereas the expression of the lipogenic gene Fas was markedly 
downregulated. In mice fed a HFD for 10 weeks, administration of EPB-53 for the last 2 
weeks attenuated body weight gain caused by the HFD. This effect is consistent with the 
well-known reported effect of FGF21 administration on body weight (Xu et al., 2009).  
 
Treatment with EPB-53 also reduced the serum levels of these lipids, whereas metformin did 
not. The reduction in serum triglycerides caused by EPB-53 might be dependent, at least 
partially, on the increase in the levels of the ATF4-target gene VLDLR (Jo et al., 2013). In 
fact, the upregulation of hepatic VLDLR via PPARα is required for the triglyceride-lowering 
effect of fenofibrate (Gao et al., 2014). Thus, we can envisage that the upregulation of hepatic 
VLDLR by EPB-53 increases the delivery of triglycerides transported by VLDL to the liver, 
reducing the availability of these lipids to be delivered to peripheral tissues, such as white 
adipose tissue. This action may contribute to the reduction in body weight. Notably, hepatic 
VLDLR upregulation following EPB-53 treatment does not result in hepatic steatosis, 
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suggesting that the uptake of triglycerides from plasma cannot compensate for the reduction 
in lipogenesis.  
 
Both EPB-53 and metformin also reduced glucose intolerance in mice fed a HFD. However, 
whereas metformin did not prevented either hepatic steatosis or hypertriglyceridemia, EPB-53 
prevented both alterations completely. The reduction in hepatic steatosis in these mice seems 
to be the result of inhibition of hepatic lipogenesis, which is consistent with the effects 
observed following FGF21 administration (Wei et al., 2012). This effect of EPB-53 was also 
observed in vitro in human hepatocytes. This finding rules out the possibility that the 
reduction in lipogenesis observed in vivo is secondary to body weight reduction. However, 
when we examined the levels of hepatic Fgf21 expression and serum levels in EPB-53-treated 
mice, no changes were observed compared to control mice, although the phosphorylated 
levels of HRI and eIF2α were increased. The lack of an increase in FGF21 in mice treated 
with EPB-53 for 2 weeks might be explained by the following mechanism. As mentioned 
above, administration of FGF21 reduces its expression in liver, as plasma and hepatic 
triglyceride levels decrease (Hanle et al., 2012). This suggests that a similar mechanism might 
also operate with EPB-53. Since EPB-53 reduced hepatic triglyceride accumulation to values 
similar to those present in control mice, once the normal hepatic lipid content is achieved, the 
effect of EPB-53 on FGF21 upregulation would be attenuated. In fact, a similar effect has 
been reported with inhibitors of fibroblast activation protein (FAP) (Sánchez-Garrido et al., 
2016). This enzyme cleaves FGF21 and its inhibition increases FGF21 levels, thereby 
lowering body weight and improving glucose tolerance in mice fed a HFD; but these effects 
are much less intense in lean mice (Sánchez-Garrido et al., 2016). Moreover, the reduction in 
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the hepatic expression and serum levels of FGF21 might be explained by the presence of 
negative feedback by which enhanced levels of FGF21 inhibit the eIF2α-ATF4 pathway 
(Jiang et al., 2014). This negative feedback mechanism would control FGF21 levels thereby 
avoiding excessive production of this hormone following EPB-53 administration when 
plasma and hepatic triglyceride levels reach normal values. Notably, this feedback mechanism 
might avoid the development of side effects (Talukdar et al., 2016; Kim et al., 2017) reported 
with long-acting FGF21 analogs due to overactivation of the FGF21 receptor. Surprisingly, 
and in contrast to EPB-53, metformin treatment was accompanied by increased hepatic and 
circulating levels of FGF21; although this increase resulted neither in an amelioration of 
hepatic steatosis nor affected the expression of genes negatively regulated by FGF21, such as 
Hsd3b5 and Mup1, which were downregulated by EPB-53. The increase in FGF21 levels 
following metformin treatment has been demonstrated to be dependent on the inhibition of 
mitochondrial complex I activity and the subsequent activation of the PKR-like endoplasmic 
reticulum (ER) kinase (PERK)-eIF2α-ATF4 pathway (Kim et al., 2013). We currently have 
no explanation for the lack of effect of the increase in FGF21 levels caused by metformin 
compared to EPB-53, although changes in the levels of total and intact serum FGF21 caused 
by differences in the activity of FAP might be implicated (Sánchez-Garrido et al., 2016). 
Confirmation of the dependence of EPB-53 effects on FGF21 was obtained using Fgf21-
knockout mice. In mice deficient in FGF21, the effects of EPB-53 were abolished. Oral 
administration of EPB-53 for 1 week upregulated hepatic expression and serum levels of 
FGF21, supporting the notion that in shorter treatments EBP-53 increases the levels of 
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Overall, the findings of this study demonstrate that oral administration of HRI activators is a 
potential strategy for the treatment of T2DM and NAFLD since it increases FGF21. It 
remains to be studied via long-term treatment whether the use of HRI activators to increase 
FGF21 levels avoids the side effects reported with long-acting FGF21 analogs. In the clinical 
setting, the use of an oral drug to induce endogenous FGF21 levels might have advantages 
over FGF21 analogs for the treatment of insulin resistance, type 2 diabetes mellitus and 
NAFLD.  
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Fig. 1. EPB-53 increases the expression of FGF21 in human Huh-7 hepatocytes.  A, 
molecular structure of EPB-53. B, FGF21 mRNA abundance in human Huh-7 hepatocytes 
exposed to 10 µM of BTCtFPU, CTdCPU, and EPB-53 for 24 h. mRNA levels are presented 
as the mean ± S.D. (n=6 per group). *p<0.05 vs. control (CT). #p<0.05 vs. BTCtFPU-treated 
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Fig. 2. Oral administration of the HRI activator EPB-53 for 4 days increases hepatic 
expression and serum FGF21 levels in mice. Mice received one daily oral gavage of vehicle 
(2% w/v cyclodextrin) or one daily oral dose of the HRI activator EPB-53 for 4 days. A, liver 
cell lysate extracts were assayed via Western blot analysis with antibodies against total and 
phospho-HRI, total and phospho-eIF2α, and ATF4. B, Fgf21 mRNA abundance in the liver. 
C, serum FGF21 levels. D, Vldlr and Chop mRNA abundance in the liver. E, Pgc-1α, Pparα, 
Cpt-1α, Mcad, and Fas mRNA abundance in the liver. Data are presented as the mean ± S.D. 
(n=6 per group) relative to control mice. *p<0.05 vs. control mice (CT). 
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Fig. 3. Oral administration of EPB-53 reduces body weight gain, and improves glucose 
intolerance in mice fed a HFD. Mice were fed standard chow, a HFD for ten weeks or a 
HFD for 10 weeks plus EPB-53 or metformin during the last two weeks. A, Body weight and 
body weight gain. B, basal glucose levels. C, glucose tolerance test and area under the curve 
(AUC). Data are presented as the mean ± S.D. (n=6 per group). *p<0.05 vs. control (CT) 
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Fig. 4. Oral administration of EPB-53 prevents fatty liver in mice fed a HFD. Mice were 
fed standard chow, a HFD for 10 weeks or a HFD for 10 weeks plus EPB-53 or metformin 
during the last 2 weeks (n=6 per group). A, H&E and Oil Red O staining of livers. Scale bar: 
100 µm. B, liver triglyceride levels. C, serum triglyceride levels. D, serum ALT levels. E, 
serum AST levels. *p<0.05 vs. control (CT) mice treated with the vehicle alone. #p<0.05 vs. 
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Fig. 5. Oral administration of EPB-53 increases the hepatic levels of phospho-HRI and 
phospho-eIF2α in mice fed a HFD. Mice were fed a standard chow, a HFD for 10 weeks or 
a HFD for 10 weeks plus EPB-53 or metformin during the last 2 weeks. A, liver cell lysates 
extracts were assayed via Western blot analysis with antibodies against total and phospho-
HRI, and total and phospho-eIF2α. B, Fgf21 mRNA abundance in the liver. C, serum FGF21 
levels. D, Mup1 mRNA abundance in the liver. E, Hsd3b5 mRNA abundance in the liver. F, 
liver cell lysates extracts were assayed via Western blot analysis with antibodies against total 
and phospho-AMPK, and VLDLR. Data are presented as the mean ± S.D. (n=6 per group) 
relative to control mice. *p<0.05 vs. control (CT) mice treated with the vehicle alone. #p<0.05 
vs. mice exposed to a HFD and treated with the vehicle alone. †p<0.05 vs. mice fed a HFD 
and treated with EPB-53. 
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Fig. 6. Oral administration of EPB-53 decreases hepatic lipogenesis in mice fed a HFD. 
Mice were fed standard chow, a HFD for 10 weeks or a HFD for 10 weeks plus EPB-53 or 
metformin during the last 2 weeks. A, Pgc-1α, Pparα, Cpt-1α, Acox1, and Mcad mRNA 
abundance in the liver. B, Srebp1c, Scd1, Fas, Gpat, and Chrebp mRNA abundance in the 
liver. C, liver cell lysate extracts were assayed via Western blot analysis with antibodies 
against FAS, PPARγ, and CD36. Data are presented as the mean ± S.D. (n=6 per group) 
relative to control mice. D, FAS, CD36 and VLDLR mRNA abundance in human Huh-7 
hepatocytes exposed to 10 µM EPB-53 for 24 h. mRNA levels are presented as the mean ± 
S.D. (n=5 per group). *p<0.05 vs. control (CT) mice or control cells treated with the vehicle 
alone. #p<0.05 vs. mice fed a HFD and treated with the vehicle alone. †p<0.05 vs. mice fed a 
HFD and treated with EPB-53. 
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Fig. 7. EPB-53 shows a dose-response relationship. Mice were fed a standard chow or a 
HFD for 3 weeks, and the last week they received one daily oral gavage of the vehicle or three 
different doses of EPB-53. A, glucose tolerance test and area under the curve (AUC). B, liver 
triglyceride levels. Fgf21 (C) and Fas (D) mRNA abundance in the liver. Data are presented 
as the mean ± S.D. (n=5 per group). *p<0.05 vs. mice fed a standard diet and treated with the 
vehicle alone. #p<0.05 vs. mice fed a HFD and treated with EPB-53. 
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Fig. 8. The effects of the HRI activator on HFD-induced glucose intolerance and hepatic 
steatosis are dependent on FGF21. Fgf21-/- mice and their wild-type (WT) littermates 
(Fgf21+/+) were fed a standard chow or a HFD for 3 weeks, and the last week they received 
one daily oral gavage of the vehicle or  EPB-53. A, Fgf21 mRNA abundance in the liver and 
serum FGF21 levels. B, glucose tolerance test and area under the curve (AUC). C, liver 
triglyceride levels. D, H&E and Oil Red O staining of livers. Scale bar: 100 µm. E, serum 
triglyceride levels. Serum ALT (F) and AST (G) levels. Data are presented as the mean ± 
S.D. (n=5 per group). *p<0.05 vs. WT mice fed a standard diet and treated with the vehicle 
alone. #p<0.05 vs. WT mice fed a HFD and treated with the vehicle alone. †p<0.05 vs. Fgf21-
null mice fed a standard diet and treated with the vehicle alone. 
 
 
